---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-23-000069"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2023-05-23T23:59:59+00:00"
generated_at: "2026-06-14T17:20:36.178005+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Evolent Health targets $1.95B revenue, $190M adj. EBITDA for 2023 at Investor Day

## Summary
- 2023 revenue outlook midpoint $1.95B; adjusted EBITDA midpoint $190M.
- Revenue CAGR of 39% from Q4 2019 to Q1 2023; Q1 2023 revenue $427.7M.
- Cross-sell opportunity of $50B out of $150B specialty TAM; revenue renewal rate ~110% in 2022.
- Performance Suite mature flow-through margins estimated at 12-18%; capital-light model emphasized.
- TTM adjusted EBITDA $132.6M; TTM revenue (ex-divested) $1.35B.

## SEC filing metadata
- accession: 0001628908-23-000069
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2023-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000069/0001628908-23-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000069/evh-20230523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-23-000069
- JSON: https://secwatch.observer/filing/0001628908-23-000069.json
- Plain text: https://secwatch.observer/filing/0001628908-23-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.